4Kobayashi S,Ide T,Sata M.Detection of YMDD motif mutations in some lamivudine untreated asymptomatic hepatitis B virus carriers[J].J Hepatol,2001,34(4):584-586.
5Zhang X,Liu C,Gong Q,et al.Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy[J].J Gastroenterol Hepatol,2003,18(12):1353-1357.
二级参考文献26
1Lai CL,Chien RN,Leung NW,et al.One year trial of lamivutine for chronic hepatitis B.N Eng J Med,1998,339:61-68.
2Zhang XX, Liu CM, Gong QM, et al. Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy. J Gastroenterolo Hepatolo, 2003, 1353-1357.
3Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut, 2000, 46: 562-568.
4Maria Buti, Rafael Esteban. Entecavir, FTC, L-RMAU, LdT and others. J Hepatol, 2003, 39: S139-S142.
5Kirishima T, Okanoue T, Daimon Y, et al. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol, 2002, 37: 259-265
6Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol Hepatol, 2003, 18: 239-245.
7The EASL Jury. EASL international consensus conference on hepatitis B. J Hepatol, 2003, 38: 533-540.
9Li LL, Chun TW, Yin ML, et al. Prophylactic lamivudine prevents hepatitis B reactivation and mortality in patients receiving immunosuppression and chemotherapy. Hepatology, 2000, 32(Pt 2): 1183.
10Liaw YF, Sung JJY, Chow WC, et al. Effects of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B: a prospective double-blined placebo-controlled clinical trial. Hepatology, 2003, 38(Suppl)1: 262A.
5Asano N. Glycosidase inhibitors: update and perspectives on practical use[J]. Glycobiology,2003,13(10):93-104.
6Mehta A, Carrouee S, Conyers B, et al. Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: therapeutic implications [J]. Hepatology, 2001,33 (6) : 1488-1495.
7Ying C, De Clercq E, Neyts J. Lamivudine, adefovir and tenofovir exhibit long-lasting anti hepatitis B virus activity in cell culture [J]. J Viral Hepat, 2000,7(1) : 79-83.
8Zoulim F. Therapy of chronic hepatitis B virus infection:inhibition of the viral polymerase and other antiviral strategies [J]. Antiviral Research,1999, 44(1): 1-30.
9Zitzmann N, Mehta AS, Carrouee S, et al. Iraino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus; implications for the development of broad spectrum anti-hepatitis virus agents [J]. Proc Natl Acad Sci USA, 1999,96(21):11878-11882.
